A clinical and business plan examined five areas in which telemedicine could be introduced to support the strategic objectives of a large health authority: coronary heart disease; links between community hospitals and local care centres and acute hospitals; store-and-forward consultations; care in the community; and mental health. The plan identified substantial clinical, organizational and economic potential benefits, which were greatest when a radical re-engineering of the service was envisaged. Similar studies in other health districts would help to test these conclusions and inform future health service planning.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1357633X010070S107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Therapist Translator: Reflections on Working With Countertransference in the Therapeutic Relationship.
Psychoanal Rev
December 2024
6601 West College Drive, Palos Heights, IL 60463, E-mail:
While developments within psychoanalytic thought have expanded our understanding of the phenomenon of countertransference and its meaning, clinicians are often left with a sense that negative countertransference is a sign of a therapist's own "unfinished business." Within the context of clinical supervision, the model of putting countertransference reactions through The Therapist Translator is introduced as a means of exploring how to best give voice to and make use of the emotional responses that arise from within the intersubjective analytic field. In this article, the authors introduce a group process dynamic that utilizes the free association of multiple clinicians to assist in "translating" relatively unformulated material into conscious, linguistic information that can be incorporated into the treatment.
View Article and Find Full Text PDFAre the 2009 Institute of Medicine gestational weight gain recommendations applicable in a contemporary South-East Asian pregnancy cohort? Results of a prospective analysis.
PLoS One
January 2025
Endocrine Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Gestational Weight Gain (GWG) modulates pregnancy outcomes and long-term offspring metabolic health. The 2009 Institute of Medicine (IOM) GWG recommendations have largely been validated in Caucasian and mono-ethnic East Asian cohorts. Asians are at higher metabolic risk at a lower body mass index (BMI), and this has prompted the World Health Organization (WHO) to identify lower BMI cut-offs for risk evaluation amongst Asians.
View Article and Find Full Text PDFThe impact of sexual behavior on facial skin aging and pigmentation: evidence from Mendelian randomization and Bayesian colocalization analyses.
Arch Dermatol Res
January 2025
Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, China.
Why CEOs need advanced education and training for optimizing decisions in the development of innovative medicinal products? justification and recommendation.
Front Pharmacol
December 2024
Charité - Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany.
Chief executives have been educated and trained how to handle business, to take executive decisions, and take care of financial and human resources in favor of the company they are leading. CEOs (chief executive officers) of innovative pharmaceutical businesses, among others, have only seldomly been trained to understand the immense time periods involved between decisions and their moment of impact, and the skills and languages used by their internal and external R&D (research and development) staff. R&D staff and regulators, however, have undergone full training, and are usually capable of understanding each other across their various specialties (among them compound finding, quality, safety, efficacy, efficiency, risk assessment and management).
View Article and Find Full Text PDFAccelerating biosimilar market access: the case for allowing earlier standing.
J Law Biosci
January 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont St. Suite 3030, Boston, MA 02120, USA.
Biosimilars, which are affordable alternatives to biologic medicines, face delays in market entry due to the current patent litigation framework under the Biologic Price Competition and Innovation Act. Currently, biosimilar manufacturers can only initiate patent litigation to attempt to clear weak and invalid patents after submitting their Biologic License Application to the Food and Drug Administration (FDA), which happens after completing extensive, and costly clinical trials. By contrast, generic drug manufacturers can start litigation earlier due to shorter development times and less stringent clinical requirements, allowing them to launch immediately after the primary patent expires.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!